Swiss National Bank Has $1.81 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Swiss National Bank cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 63,300 shares of the specialty pharmaceutical company’s stock after selling 600 shares during the quarter. Swiss National Bank’s holdings in Collegium Pharmaceutical were worth $1,814,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Barclays PLC grew its holdings in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares during the period. Sanctuary Advisors LLC raised its position in shares of Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $695,000 after acquiring an additional 1,731 shares during the last quarter. FMR LLC raised its position in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 35,439 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock valued at $2,686,000 after purchasing an additional 55,572 shares during the period.

Analyst Ratings Changes

A number of equities research analysts recently commented on COLL shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th. Finally, Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Insider Activity at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the sale, the chief financial officer now owns 164,269 shares in the company, valued at approximately $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $29.71 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company’s 50 day moving average price is $30.36 and its two-hundred day moving average price is $32.45. The company has a market capitalization of $935.45 million, a P/E ratio of 12.81 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.